PROCEPT BioRobotics to Report Third Quarter 2022 Financial Results on November 3, 2022

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

REDWOOD CITY, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2022 after market close on Thursday, November 3, 2022. The Company’s management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by following one of the below links:

Live audio of the webcast will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com.

An archived recording will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com. The webcasts will be available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. PROCEPT BioRobotics has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact:
Matt Bacso, CFA
VP, Investor Relations and Business Operations
m.bacso@PROCEPT-BioRobotics.com

Staff

Recent Posts

CoVet Expands Clinical Leadership with Launch of In-House Medical Department

Veterinary AI leader CoVet introduces a dedicated Medical Department to ensure clinical accuracy, real-world relevance,…

6 hours ago

New ASTHO Legal Map Illuminates State and Territorial Suicide Prevention Infrastructure

ARLINGTON, Va., July 24, 2025 /PRNewswire/ -- The Association of State and Territorial Health Officials…

6 hours ago

Loomis expands its Pharma business by acquiring Kipfer-Logistik

STOCKHOLM, Sweden, July 24, 2025 /PRNewswire/ -- Loomis AB has, through its subsidiary Loomis International…

6 hours ago

HealthArc and PatchRx Partner to Boost Medication Adherence in Pain Management

Integrated RTM solution to deliver real-time medication adherence insights for pain and mental health practices.…

6 hours ago

Loopback Analytics Welcomes Industry Leader Elizabeth Cherry as Vice President of Access Solutions

DALLAS, July 24, 2025 /PRNewswire/ -- Loopback Analytics is excited to welcome Elizabeth Cherry, PharmD,…

6 hours ago

123Invent Inventor Develops Modified Glasses to Assist with Reading (BRA-8028)

PITTSBURGH , July 24, 2025 /PRNewswire/ -- "I wanted to create reading glasses like to no…

6 hours ago